Viking Therapeutics shares fall 21.36% in premarket after announcing positive results for VK2735 in obesity trial.

Viking Therapeutics, Inc. plunged 21.36% in premarket trading, following the announcement of positive results from the VENTURE-Oral Phase 2 trial of its oral VK2735 for obesity, with an average weight loss of 12.2% over 13 weeks compared to 1.3% for the placebo. The company is a clinical-stage biopharmaceutical company focused on developing new therapies for metabolic and endocrine disorders, with its GLP-1/GIP dual agonist VK2735 advancing in oral and subcutaneous formulations for obesity treatment. The weight loss drug sector was boosted by the FDA approval of a new indication for Novo Nordisk's Wegovy, indirectly lifting related stocks today.